Sasanlimab Prolongs EFS When Combined with BCG Induction and Maintenance in Patients with BCG-naive High-Risk NMIBC By Ogkologos - July 22, 2025 561 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CREST study Source RELATED ARTICLESMORE FROM AUTHOR In Memory of Hernán Cortés-Funes: Former ESMO President and Pioneer in Medical Oncology Immune Pathways Help Identify Patients with Cancer and HIV Most Likely to Experience Reservoir Decay with Anti-PD1 Therapy Shaping Future Oncology Leaders: ESMO Broadens Its Career Development Opportunities MOST POPULAR FDA Approves Azacitidine for Newly Diagnosed Juvenile Myelomonocytic Leukaemia June 2, 2022 Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent... November 24, 2025 Physical Activity May Lessen the Effects of Chemobrain, Study Finds August 26, 2021 FDA Approves Asciminib for Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia November 3, 2021 Load more HOT NEWS Loss of Y Chromosome in Men Makes Bladder Cancer More Aggressive Breast Cancer Survivor Given 12 Months to Live After Left Side... An Alternative Model for Genetic Testing Delivery Proposed with Posttest Counselling... FDA Grants Accelerated Approval to Futibatinib for Cholangiocarcinoma
